ONC BeOne Medicines (ONC) Q3 FY25 earnings call
BeOne Medicines delivered a strong Q3 FY25, driven by exceptional BRUKINSA performance, which achieved global leadership and surpassed $1 billion in quarterly sales. The company also advanced its pipeline with Sonro receiving breakthrough designation and several early-stage solid tumor assets reaching proof-of-concept. Management emphasized a disciplined R&D strategy and balance sheet strength, while acknowledging a delayed BRUKINSA trial readout and seasonal U.S. market dynamics.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
ONC operating KPIs by quarter
| KPI | Dec 2025 Q4 FY25 | Mar 2026 Q1 FY26 | Jun 2026 Q2 FY26 | Change vs prior quarter |
|---|---|---|---|---|
| Employees | <12KAnd on behalf of everyone here, I really want to thank the broader oncology community, the patients and families who inspire our work, the clinicians who partner with us every day and our almost 12,000 employees all around the world who continue to raise the bar.Source: earnings call transcript | 12K+I really want to thank the patients and the families that we serve, our physicians and our partners and our more than 12,000 colleagues and their families who focus and urgency make our progress possible.Source: earnings call transcript | 12K+And we do want to just take a moment to thank the patients, their families that we're serving, the physicians, our partners and our more than 12,000 colleagues and their families who focus with urgency every day to make this progress possible.Source: earnings call transcript | — |
Operating figures the company stated on at least two of the calls shown, checked against each call's transcript. Click a figure to read the sentence. A dash means it was not stated that quarter.
Inve summary of the company's earnings call; see how call summaries are prepared. Not investment advice.